Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 HOUSTON , Feb. 13, 2025 /PRNewswire/ -- Moleculin Biot
First of many site approvals, including sites in the US, Europe and the Middle East, expected throughout Q1-Q3 2025 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clin
Moleculin Participates in Virtual Investor "What This Means" Segment
08:30am, Monday, 27'th Jan 2025
– Walter Klemp, CEO of Moleculin, provides an update on the Company's Phase 3 pivotal trial of Annamycin for the treatment of AML patients who are refractory to or relapsed after induction therapy (
– Received US Institutional Review Board (IRB) approval for pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) and engaged leading contract research organization (CRO); On track to begin
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
08:00am, Wednesday, 11'th Dec 2024
Abstract published as part of the American Society of Hematology (ASH) Annual Meeting Study shows Annamycin effectively targets both Cytarabine (Ara-C) and Venetoclax resistant acute myeloid leukemia
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
08:15am, Monday, 18'th Nov 2024
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model New preliminary clinical results show Annamycin plus A
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
08:15am, Thursday, 14'th Nov 2024
Amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects Company remains on track for first subject treated in p
Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Trial designed for possible accelerated approval of Annamycin
Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript
11:17am, Monday, 11'th Nov 2024
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q3 2024 Earnings Conference Call November 11, 2024 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman and CEO John Paul Waymack - Senior
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
07:05am, Monday, 11'th Nov 2024
- On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
09:00am, Tuesday, 05'th Nov 2024
HOUSTON , Nov. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
08:30am, Monday, 04'th Nov 2024
Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON , Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MB
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
08:40am, Thursday, 17'th Oct 2024
Access the transcript here HOUSTON , Oct. 17, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
08:30am, Monday, 07'th Oct 2024
Live webcast discussion featuring internationally renowned Acute Myeloid Leukemia (AML) Key Opinion Leaders Ongoing progress of pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed
Moleculin to Present at Two Upcoming Investor Conferences
09:00am, Friday, 04'th Oct 2024
HOUSTON , Oct. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting h
